Diana Ernst, RPh, Author at MPR

Diana Ernst, RPh

All articles by Diana Ernst, RPh

Vedolizumab Tops Adalimumab in Head-to-Head Ulcerative Colitis Trial

Vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, was found to be superior to adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in achieving clinical remission in patients with moderately to severely active ulcerative colitis (UC), according to results from a phase 3b head-to-head trial.

Lonsurf Gains Metastatic Gastric Cancer Indication

The Food and Drug Administration has approved Lonsurf ((trifluridine and tipiracil; Taiho Oncology) for the treatment of adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.